A first-of-its kind hormone replacement therapy that more closely replicates the natural circadian and ultradian rhythms of our hormones has shown to improve symptoms in patients with adrenal conditions.
Final Enrollment in CAHmelia-203 to Exceed Target Due to Substantial Patient Interest
CAHmelia-203 Topline Results Anticipated in the First Quarter of 2024
CAHmelia-204 Completion of Enrollment.
Researchers delve into endocrine causes of hypertension (HTN), revealing key culprits like primary aldosteronism and Cushing's syndrome. The study also evaluates the efficacy of various treatments, offering valuable insights for tackling this widespread health issue.
Neurocrine Biosciences Inc.’s positive top-line data from the phase III study called Cahtalyst in classic congenital adrenal hyperplasia (CAH) further whetted Wall Street’s appetite for soon-to-come results in the same indication from Spruce Therapeutics Inc.